About Syntis
Syntis is a Healthcare company based in Boston (United States) founded in 2021 by Robert Langer, Rahul Dhanda, and Giovanni Traverso. Drug compounding services are provided by Syntis in healthcare. Syntis has raised $65.88 million across 5 funding rounds from investors including NIH, Colorcon and W. R. Berkley. Its chief executive, as recorded, is Rahul Dhanda. Syntis offers products and services including SYNT-101. Its focus areas include Life Sciences, Obesity, Drugs and GLP-1 Based. Its legal entity is Syntis Bio, Inc. Its competitors include Fagron, Revelation Pharma and Pharmedium.
Company details
Syntis was founded in 2021 in Boston, United States, by co-founders Robert Langer, Rahul Dhanda, and Giovanni Traverso. The company operates within the pharmaceutical sector, where customized drug compounding services are delivered. These services involve the preparation of tailored medications to meet specific patient requirements. Focus is placed on sterile compounding processes compliant with regulatory standards, supporting healthcare providers across the region.
- Headquarters Boston, United States
- Founders Robert Langer, Rahul Dhanda, Giovanni Traverso
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website syntis.bio
- Social LinkedIn X
- Legal Name Syntis Bio, Inc.
- Total Equity Funding$65.88M (USD)
in 5 rounds
- Latest Funding Round$33M (USD), Series A
Jul 2025
- InvestorsNIH
& 10 more
Products & Services of Syntis
Syntis offers a comprehensive portfolio of products and services, including SYNT-101.
Oral treatment for obesity that mimics gastric bypass effects.
Funding Insights of Syntis
Syntis has successfully raised a total of $65.88M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $33 million completed in July 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $65.88M
- Total Rounds 5
- Last Round Series A — $33M
- First Round $11.19M
(Aug 2022)
- Investors Count 11
All 5 funding rounds of Syntis with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | $5M | Grant | – | – | |
| Jul 2025 | $33M | Series A | – | Cerberus Capital Management | |
| Dec 2024 | $6.32M | Series B | – | – | – |
| Jan 2023 | $15.37M | Series B | – | – | – |
| Aug 2022 | $11.19M | Series B | – | – | – |
11 investors in total: 11 institutional.
Investors in Syntis
Syntis has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Colorcon and W. R. Berkley.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
| woorivp.us | ||||
Early-stage life sciences and tech focused VC firm investing primarily in the US | boldcapitalpartners.com | Santa Monica, United States | ||
Safar Partners is engaged in investing in technology startups. | 2018 | safar.partners | Cambridge, United States | |
Portal Innovations is engaged in funding life sciences startups. | portalinnovations.com | Chicago, United States | ||
Private equity and debt firm focused on multiple sectors | cerberus.com | New York, United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Mansueto Office is engaged in investment and real estate management. | mansuetoffice.com | Chicago, United States | ||
Insurance subsidiaries are managed through a global holding structure. | 1967 | berkley.com | Greenwich, United States | |
Developer of specialty excipients and corporate-backed venture capital fund focused on healthcare startups | 1961 | colorcon.com | Harleysville, United States | |
Offers fast and reliable testing for cannabis potency, safety, and compliance. | 2021 | apollolabscorp.com | Scottsdale, United States |
Investor details for Syntis
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Syntis
3 people are tracked at Syntis (3 in leadership).
| Name | Role | Group |
|---|---|---|
Robert Langer | Co-Founder | Leadership |
Rahul Dhanda | Co-Founder & CEO | Leadership |
Giovanni Traverso | Co-Founder | Leadership |
Complete people profiles for Syntis
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Syntis
3 dated milestones of Syntis across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Syntis is founded.
- Funding First funding round of $11.2M.
- Funding Latest funding round, Series A, of $33.0M.
Competitors of Syntis
Syntis has 3 listed competitors in our database. They include Fagron, Revelation Pharma and Pharmedium.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| fagron.com | 1990 | Saint Paul, United States | 3,315 | Drug compounding services are provided by Fagron. | ||
| revcustomrx.com | 2020 | Greenwood Village, United States | A network of compounding pharmacies is operated nationwide. | |||
| pharmedium.com | 2003 | Lake Forest, United States | Drug compounding services are provided to healthcare facilities nationwide. |
Detailed competitors of Syntis
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Syntis
The website of Syntis (syntis.bio) receives about 1.7K visits a month.
- Monthly visits1.7K
▲ 2.6% vs previous month
Top companies in Obesity
3 companies that operate in the same segment as Syntis (Obesity) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Bioinformatics platform is provided for biomarkers and drug discovery. | 2015 | Vallejo, California, United States | USD 293.9 M | USD 8.99 M | 64 | |
Disease-modifying therapies for metabolic diseases are developed. | 2008 | Berkeley, California, United States | USD 385.52 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Syntis
Complete news archive for Syntis
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Syntis
Syntis was founded in 2021 and raised its 1st funding round 1 year after it was founded.
Syntis is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Rahul Dhanda is the CEO of Syntis, as recorded in our data. They have also founded this company.
Syntis is a funded company, having raised a total of $65.88M across 5 funding rounds to date. The company's 1st funding round was a Series B of $11.19M, raised on Aug 2022.
Syntis was founded in 2021 in Boston, United States, by co-founders Robert Langer, Rahul Dhanda, and Giovanni Traverso. The company operates within the pharmaceutical sector, where customized drug compounding services are delivered. These services involve the preparation of tailored medications to meet specific patient requirements. Focus is placed on sterile compounding processes compliant with regulatory standards, supporting healthcare providers across the region.
Syntis's top competitors include Fagron, Pharmedium and Revelation Pharma.
Syntis offers SYNT-101.
Syntis has 11 investors. Key investors include NIH, Colorcon, W. R. Berkley, Cerity Partners, and Mansueto Office.
Syntis operates through Syntis Bio, Inc..